Ultimele actualizari :
08/05/2024
Antiviral   Ganciclovir sodium  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie Pdf
   Formula chimica  

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Ceptyl Mexic
Ciganclor Argentina
Citovirax Italia
Cymevan Franta
Cymeven Germania
Cymevene Australia, Austria, Belgia, Brazilia, Chilli, Columbia, Croatia, Danemarca, Ecuador, Egipt, Elvetia, Emiratele Arabe Unite, Finlanda, Grecia, Iran, Irlanda, Islanda, Italia, Luxemburg, Malaezia, Marea Britanie, Mexic, Norvegia, Noua Zeelandă, Olanda, Peru, Polonia, Portugalia, Rusa, Spania, Suedia, Turcia, Ungaria, Venezuela
Cymevir Brazilia
Cytovene Canada, SUA
Ganciclovir Argentina, Canada, Chilli, Ecuador, Franta, Germania, Mexic, SUA
Gavir India
Inglav Mexic
Natclovir India
Pharcigave Mexic
Umecortil Columbia, Mexic
Viraprex Mexic
Bibliografie   Injectabil   Bibliografie : Ganciclovir sodium  
Tip Publicare
3 Ziar Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
4 Ziar Zazempa V, Morgenszejn J, Paul M, Astier A.
Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité.
Act Pharm Biol Clin 1995 ; 8: 525-528.
36 Ziar Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59 Ziar Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
67 Ziar Outman WR, Mitrano FP, Baptista RJ.
Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1538-1539.
69 Ziar Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA.
Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections.
Am J Hosp Pharm 1986 ; 43: 2810-2812.
70 Ziar Silvestri AP, Mitrano FP, Baptista RJ, Williams DA.
Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days.
Am J Hosp Pharm 1991 ; 48: 2641-2643.
72 Ziar Johnson CE, Jacobson PA, Chan E.
Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions.
Am J Hosp Pharm 1994 ; 51: 503-508.
73 Ziar Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
74 Ziar Mulye NV, Turco SJ, Speaker TJ.
Stability of ganciclovir sodium in an infusion-pump syringe.
Am J Hosp Pharm 1994 ; 51: 1348-1349.
76 Ziar Parasrampuria J, Li LC, Stelmach AH, Sykes TR, Gordon GA.
Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days.
Am J Hosp Pharm 1992 ; 49: 116-118.
81 Ziar Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Ziar Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
88 Ziar Mole L, Oliva C, O?Hanley P.
Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis.
J Acquired Immune Defic Syndr 1992 ; 5: 354-358.
99 Ziar Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Ziar Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Ziar Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
201 Ziar Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531.
244 Ziar Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
245 Ziar Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M.
Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes.
J Pharm Belg 1992 ; 47: 494-498.
248 Ziar Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Ziar Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Ziar Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Ziar Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
299 Ziar Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Ziar Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Ziar Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Ziar Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Ziar Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Ziar Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
479 Ziar Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492 Ziar Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Ziar Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
604 Laborator Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
905 Ziar Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Ziar Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1410 Ziar Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Ziar Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Ziar Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1625 Ziar Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1754 Ziar Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 Ziar Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Ziar Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Ziar Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 Ziar Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3626 Laborator Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit
Astellas Pharma 2014
3662 Laborator Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014
3728 Ziar Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3796 Ziar Morlet N, Young S, Naidoo D et al.
High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study.
Br Ophtalmol 1995 ; 79: 753-755.
3883 Laborator Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
4021 Ziar Guichard N, Bonnabry P, Rudaz S, Fleury S.
Long-term stability of ganciclovir in polypropylene containers at room temperature.
J Oncol Pharm Practice 2017 ;25,2: 303-308
4521 Ziar Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020

  Mentions Légales